Paul Matteis
Stock Analyst at Stifel
(2.99)
# 1,349
Out of 5,134 analysts
125
Total ratings
45.24%
Success rate
0.44%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $445 → $466 | $477.32 | -2.37% | 21 | Feb 13, 2026 | |
| QURE uniQure | Maintains: Buy | $50 → $40 | $21.75 | +83.91% | 3 | Dec 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $183 → $188 | $127.76 | +47.15% | 11 | Dec 11, 2025 | |
| LBRX LB Pharmaceuticals | Maintains: Buy | $27 → $35 | $24.12 | +45.11% | 2 | Dec 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $36 → $39 | $15.28 | +155.24% | 5 | Dec 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $495 → $508 | $332.61 | +52.73% | 16 | Dec 11, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $24 → $25 | $22.95 | +8.93% | 6 | Dec 11, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $28 | $17.25 | +62.32% | 1 | Nov 21, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Hold | $2 → $3 | $3.54 | -15.25% | 3 | Nov 17, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Hold | $73 → $61 | $59.95 | +1.75% | 11 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $144 → $202 | $195.62 | +3.26% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $43 → $67 | $81.33 | -17.62% | 6 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $6.79 | +76.73% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $102.53 | -8.32% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $38.03 | -15.86% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $15.99 | +100.13% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $7.63 | +44.17% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.97 | +103.05% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $19.26 | -48.08% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $17.42 | +244.43% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $32.90 | +9.42% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $29.06 | +20.44% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $14.69 | +97.41% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.28 | +218.47% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.53 | +2,164.15% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $14.99 | +113.48% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.45 | +1,002.04% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $12.59 | +408.34% | 1 | Feb 21, 2018 |
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Hold
Price Target: $445 → $466
Current: $477.32
Upside: -2.37%
uniQure
Dec 11, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $21.75
Upside: +83.91%
Neurocrine Biosciences
Dec 11, 2025
Maintains: Buy
Price Target: $183 → $188
Current: $127.76
Upside: +47.15%
LB Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $27 → $35
Current: $24.12
Upside: +45.11%
Dyne Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $15.28
Upside: +155.24%
Alnylam Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $495 → $508
Current: $332.61
Upside: +52.73%
ACADIA Pharmaceuticals
Dec 11, 2025
Maintains: Hold
Price Target: $24 → $25
Current: $22.95
Upside: +8.93%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $17.25
Upside: +62.32%
Neumora Therapeutics
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $3.54
Upside: -15.25%
BioMarin Pharmaceutical
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $59.95
Upside: +1.75%
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $195.62
Upside: +3.26%
Oct 6, 2025
Maintains: Hold
Price Target: $43 → $67
Current: $81.33
Upside: -17.62%
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $6.79
Upside: +76.73%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $102.53
Upside: -8.32%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $38.03
Upside: -15.86%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $15.99
Upside: +100.13%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $7.63
Upside: +44.17%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.97
Upside: +103.05%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $19.26
Upside: -48.08%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $17.42
Upside: +244.43%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $32.90
Upside: +9.42%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $29.06
Upside: +20.44%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $14.69
Upside: +97.41%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $6.28
Upside: +218.47%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $0.53
Upside: +2,164.15%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $14.99
Upside: +113.48%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $2.45
Upside: +1,002.04%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $12.59
Upside: +408.34%